Piper Sandler Maintains Overweight on Camp4 Therapeutics, Lowers Price Target to $12
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Piper Sandler analyst Edward Tenthoff maintains Camp4 Therapeutics (NASDAQ:CAMP) with a Overweight and lowers the price target from $18 to $12.
Piper Sandler analyst Edward Tenthoff maintains Camp4 Therapeutics (NASDAQ:CAMP) with a Overweight and lowers the price target from $18 to $12.